Research · Sep 3, 2026
PLXS Plexus Corp Thesis 2026: Healthcare Aerospace EMS Drives High Mix Complex Product Realization Capital Return
Plexus Corp. (NASDAQ: PLXS) FY2026 thesis centers on continued Healthcare/Life Sciences + Aerospace/Defense EMS pipeline (~$2.50-2.90B revenue) + Industrial EMS + Engineering Solutions pipeline (~$1.50-1.75B revenue) under continued President + CEO Todd Kelsey since 2016 (~9-year tenure as Plexus CEO; selected post-2016 succession from Dean Foate retirement after ~14-year tenure 2002-2016; selected primary architect of post-2016 strategic focus toward Healthcare/Life Sciences + Aerospace/Defense + Industrial high-complexity low-to-mid-volume high-mix EMS positioning + post-2016-2025 manufacturing footprint optimization). FY2025 revenue ~$4.10-4.60B (+5-15% YoY) with adj. EPS ~$6.50-7.50 reflecting continued ~$0.30-0.40B aggregate adj. EBITDA. PLXS operates 1 reportable segment with 3 market sectors: Healthcare/Life Sciences ~45-48% revenue ($1.85-2.10B) + Industrial ~37-42% revenue ($1.50-1.75B) + Aerospace/Defense ~14-18% revenue ($0.65-0.80B) with geographic mix (manufacturing) Americas ~35-40% + Asia Pacific ~45-50% + EMEA ~10-15%. Healthcare/Life Sciences + Aerospace/Defense EMS pipeline (~$2.50-2.90B revenue + ~58-63% revenue mix): selected primary Healthcare/Life Sciences (~$1.85-2.10B; medical device + diagnostic + surgical + drug delivery + In-Vitro Diagnostics + FDA-regulated ISO 13485 manufacturing + cleanroom + ~$1.5-2.5B aggregate Healthcare/Life Sciences funnel) + Aerospace/Defense (~$0.65-0.80B; commercial aerospace + defense electronics + radar + avionics + space + AS9100 + ITAR + ~$1.0-2.0B aggregate Aerospace/Defense funnel) + ~$3.0-4.5B aggregate trailing 12-month total new program wins funnel. Industrial EMS + Engineering Solutions pipeline (~$1.50-1.75B revenue + ~37-42% revenue mix; cyclical recovery thesis): selected primary Industrial (semiconductor capital equipment + test & measurement + factory automation + energy + broadband + networking + ~$2.0-3.0B aggregate Industrial funnel) + Engineering Solutions (product design + development + sustaining engineering + value-add manufacturing engineering + ~10-15% aggregate Engineering Solutions attach rate on new program wins + ~higher gross margin engineering content) + Aftermarket Services (repair + refurbishment + reverse logistics) + post-2024 semiconductor capital equipment + factory automation cyclical recovery + Industrial demand normalization. Capital position + balance sheet: ~$0.00 aggregate annual dividend (no regular dividend; buyback-focused capital return) + ~$100-300M aggregate FY2025 buybacks + aggregate capital return ~$100-300M FY2025 + aggregate cash + investments ~$0.3-0.5B + ~$0.3-0.5B aggregate gross debt + ~$0.0-0.2B aggregate net debt + net leverage ~~0-0.8x Net Debt/EBITDA + non-investment-grade BB+/Ba1 credit rating + ~26-28M aggregate diluted shares. FY2026 base case ~$4.40-4.95B aggregate revenue + ~$7.25-8.50 adj. EPS + ~$100-350M aggregate capital return; bull case Healthcare/Life Sciences + Aerospace/Defense EMS pipeline acceleration (medical device + diagnostic + surgical + drug delivery + In-Vitro Diagnostics demand + commercial aerospace + defense electronics + radar + avionics + space demand + ~$1.6-2.7B Healthcare/Life Sciences funnel + ~$1.1-2.2B Aerospace/Defense funnel) + Industrial EMS + Engineering Solutions pipeline acceleration (semiconductor capital equipment + factory automation cyclical recovery continuation + Engineering Solutions attach rate expansion + ~$2.2-3.3B Industrial funnel) drives ~$4.70-5.25B aggregate revenue + ~$8.50-10.00 EPS; bear case Jabil + Flex + Celestica + Sanmina + Benchmark + Kimball + Fabrinet + Integer + Cretex Medical competitive intensification + Healthcare/Life Sciences + Aerospace/Defense end-market cycle considerations + semiconductor capital equipment cycle considerations (ASML + Applied Materials + Lam Research + KLA capex cycle) + factory automation cycle considerations + Industrial end-market cycle considerations + customer concentration considerations + manufacturing footprint optimization considerations + post-2016 Todd Kelsey CEO succession planning considerations (~9-year tenure) drives ~$4.00-4.30B revenue + ~$5.75-6.75 EPS.